Pharmacoeconomic evaluations of antifungal therapies

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1751-1758

  Hennen, Cynthia R ^a  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Candida; Cost effective; Drug acquisition; Echinocandin; Indirect cost; Pharmacoeconomics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HOSPITAL COST; HUMAN; INVASIVE CANDIDIASIS; KIDNEY FAILURE; MAINTENANCE DRUG DOSE; META ANALYSIS; NEPHROTOXICITY; SYSTEMATIC REVIEW; UNITED STATES;

ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; MYCOSES;

EID: 67650474077     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Douglas HR, Normand C. Economic evaluation: what does a nurse manager need to know? J Nurs Manag 2005;13:419-27
2. Johnson MD, Kleinberg M, Danziger L, et al. Pharmacoeconomics of antifungal pharmacotherapy - challenges and future directions. Expert Opin Pharmacother 2005;6:2617-32
3. Lopert R, Lang DL, Hill SR. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis - a technique for decision-making at the margin. J Clin Pharm Ther 2003;28:243-9
4. Saint S, Chenoweth C, Fendrick AM. The role of economic evaluation in infection control. Am J Infect Control 2001;29:338-44
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-63
6. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7
7. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30
8. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17
9. Blot SI, Vandewoude KH, Hoste EA, et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002;113:480-5
10. Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2008;34:292-9
11. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7
12. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9
13. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30
14. Giamarellou H, Antoniadou A. Epidemiology, diagnosis, and therapy of fungal infections in surgery. Infect Control Hosp Epidemiol 1996;17:558-64
15. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-35
16. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002;15:569-74
17. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-43
18. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30
19. Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect 2007;1:74-92
20. Garrouste-Orgeas M, Timsit JF, Tafflet M, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006; 42:1118-26
21. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7
22. Puzniak L, Teutsch S, Powderly W, et al. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004;25:628-33
23. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31
24. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55
25. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5
26. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35-9
27. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-601
28. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-8
29. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5:26-34
30. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9
31. Dixon S, McKeen E, Tabberer M, et al. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 2004;22:421-33
32. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005;31:1479-87
33. Ho KM, Lipman J, Dobb GJ, et al. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit Care 2005;9:R710-17
34. Playford EG, Webster AC, Sorrell TC, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57:628-38
35. Shorr AF, Chung K, Jackson WL, et al. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005;33:1928-35
36. Vardakas KZ, Samonis G, Michalopoulos A, et al. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006;34:1216-24
37. Nomura K, Kawasugi K, Morimoto T. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. Eur J Cancer Care (Engl) 2006;15:44-50
38. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997;17:373-81
39. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-41
40. Golan Y, Wolf MP, Pauker SG, et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 2005;143:857-69
41. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27
42. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6
43. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402
44. Bodhe PV, Kotwani RN, Kirodian BG, et al. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection. J Assoc Physicians India 2002;50:662-70
45. Girois SB, Chapuis F, Decullier E, et al. Adverse effects of antifungal therapies in invasive fungal infections: review and metaanalysis. Eur J Clin Microbiol Infect Dis 2006;25:138-49
46. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93
47. Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007;78:532-9
48. Kaskel P, Tuschy S, Wagner A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008;87:311-19
49. Stam WB, Aversa F, Kumar RN, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health 2008; May 20 [Epub ahead of print].
50. Wingard JR, Leather HL, Wood CA, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm 2007;64:637-43
51. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002; 49(Suppl 1):81-6
52. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-83
53. Kuti JL, Kotapati S, Williams P, et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22:301-10
54. Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24:1743-53
55. Wingard JR, Wood CA, Sullivan E, et al. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther 2005;27:960-9
56. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35